Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Clinical trial NCT06923397 · RECRUITING

Trial details

NCT number: NCT06923397
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Lymphoma Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Sedentary Behavior

Start date: 2025-06-05
Primary completion: 2026-11-28
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.